興科蓉醫藥(6833.HK):醫美佈局再下一城,產業基地獲當地政府支持
興科蓉醫藥(6833.HK)1月6日在港交所發佈公吿稱,收到成都天府國際生物城管理委員會函件。根據該函件,公司醫美產品產業化基地將獲得成都天府國際生物城管理委員會的全力支持。
成都天府國際生物城管理委員會(下稱“管委會”)在函件中表示,將全力支持興科蓉公司的智能醫美產業園項目及其對聚己內酯等醫美產品的研究及發展和產業化,協助興科蓉公司在醫美產品領域建立重要研究及發展策源地及產業化基地。管委會表示,已設立專項工作小組協調有關實施醫美產業園項目事宜及日常聯絡工作。
公開資料顯示,興科蓉是中國醫藥行業領先的營銷、推廣及渠道管理服務供貨商,也是中國血漿藥品領域唯一的營銷、推廣及渠道管理服務供貨商。根據公司資料,2020年興科蓉醫藥的人血白蛋白注射液的市場佔有率劑銷量已達全國第二。興科蓉醫藥專注於進口血液製品的經銷長達十年之久,依託其在該領域的領先優勢及完善的營銷推廣渠道,該公司進一步佈局醫美領域,於去年9月份與北京諾康達就“少女針”的開發進行了合作,投資人民幣8850萬元,以期在醫美領域建立自主研發體系,進一步完善公司從研發生產到銷售的一體化產業。
此次獲成都天府國際生物城支持的產業基地項目當中即包含“少女針”相關醫美產品。據悉,“少女針”(聚己內酯,PCL)是填充及刺激再生的產品,被視為傳統醫美產品玻尿酸升級換代的產品,目前在歐洲、美國已實現對玻尿酸的全面替代。從發展策略上來看,合作開發“少女針”是興科蓉進入醫美市場的第一步,後續該公司將依託聚己內酯原材料開發系列產品“PCL+X”,衍生出多種醫美產品,適用於各種部位。可以預計,依託成都醫美產品產業基地,興科蓉開發的一系列醫美產品後續或將打開更大的增長空間。興科蓉也期望藉此將公司打造成為國內聚己內酯行業從技術、生產到銷售均領先的企業。
據公開資料介紹,成都天府國際生物城位於成都市西南,目標是建成世界一流生物產業園區。截至目前,園區已吸引到諾獎團隊5個、院士級團隊4個、高層次人才團隊51個、各類專業人才3000人,累計落户項目150個,總投資超1100億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.